Mobia Medical's Troubled IPO Debut Raises Red Flags For Investors.

Mobia Medical's Troubled IPO Debut Raises Red Flags For Investors. The medical device company's shares plummeted over 20 percent on their first trading day, signaling market skepticism despite impressive revenue growth. While the company's Vivistim Paired VNS stroke recovery system doubled revenues to 32 million dollars in 2025, operating losses nearly doubled as well. The fundamental challenge remains clear: Mobia cannot convert strong sales momentum into profitability. With mounting per-patient costs and a persistent lack of operating leverage, the company faces significant headwinds. Although Mobia maintains approximately 200 million dollars in net cash, this provides only temporary cushion. The market's immediate rejection suggests investors question whether the company can achieve sustainable profitability in the competitive stroke recovery market.